Mylan's (MYL) EpiPen is going to start selling a generic version of its EpiPen allergy treatment with more than a 50% discount. The move follows 20 states filed a lawsuit against the drugmaker along with a US government investigation.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.